AIDS Alert Archives – March 1, 2006
March 1, 2006
View Issues
-
Treatment interruption continues to be controversial strategy in HIV care
Despite national media headlines announcing the end of treatment interruption as an antiretroviral strategy, the most recent studies show mixed results, and so the research probably will continue. -
Special Coverage: Retroviruses Conference 2006: HIV seroconversion time is more similar among patients than not
North Carolina investigators came across a very unusual HIV case that raised the question of how long it takes for people infected with HIV to experience seroconversion. -
Special Coverage: Retroviruses Conference 2006: Earlier treatment and more effective drugs needed in battle against HIV
A better clinical strategy with HIV care would be to begin treatment soon after infection, an HIV researcher suggests. -
Adherence Strategies: HIV patients' moods, social support have impact on medication adherence
Investigators have found that HIV-infected patients who use an avoidance-oriented coping strategy and who have poor social support and a generally negative mood have poorer medication adherence. -
Special Coverage: Retroviruses Conference 2006: Study says triple NRTI regimens are not as effective as those also containing NNRTI
A recent study that compares non-protease inhibitor regimens found that patients taking a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen do not achieve as effective viral suppression as those taking a regimen containing two NRTIs and one non-nucleoside reverse transcriptase inhibitor (NNRTI). -
Anal cancer incidence rates increased in antiretroviral era
Investigators compared United States surveillance data for cancer in the pre-HIV era, HIV era, and antiretroviral treatment era and found that squamous cell carcinoma of the anal canal incidence rates increased significantly in the latter era. -
FDA Notifications: FDA will hold public workshop on NAT on March 8 at NIH
The Food and Drug Administration will be conducting a public workshop entitled Behavior-Based Blood Donor Deferrals in the Era of Nucleic Acid Testing [NAT).